SOUTH SAN FRANCISCO, Calif. & TOKYO - Twist Bioscience (NASDAQ:TWST) Corporation (NASDAQ:TWST) and bitBiome Inc. have announced the release of a new Transaminase Enzyme Screening Kit, a collection of forty-eight diverse transaminase enzymes.
This product aims to support the pharmaceutical industry by providing a more environmentally friendly alternative for synthesizing chiral amines, which are key components in drug manufacturing.
The collaboration between the two companies combines Twist Bioscience's high-capacity DNA synthesis technology with bitBiome's extensive database of over two billion microbe sequences.
The Transaminase Enzyme Screening Kit is designed to facilitate the discovery and implementation of improved enzymes for biocatalysis, especially in the creation of active pharmaceutical ingredients (APIs).
Yuji Suzuki, CEO of bitBiome, expressed enthusiasm for the partnership, highlighting the synergy between bitBiome's diverse sequence collection and Twist Bioscience's large-scale DNA synthesis capabilities.
Emily Leproust, CEO and co-founder of Twist Bioscience, also commented on the venture, stating the kit enhances their DNA synthesis services and offers a novel approach to enzyme engineering and development in biocatalysis.
Twist Bioscience is recognized for its disruptive DNA synthesis platform, which utilizes a silicon chip to 'write' DNA, facilitating the production of various synthetic DNA-based products.
These products span multiple industries, including healthcare and academic research. The company is also exploring opportunities in digital DNA data storage and biologics drug discovery.
bitBiome leverages its single-cell microbial genome analysis technology and bioinformatics expertise to offer a comprehensive enzyme discovery and engineering platform. Their services are aimed at improving biomanufacturing and fostering new industry developments.
This article is based on a press release statement and does not contain any promotional content or endorsement of claims. The information presented is intended to provide an objective and factual report on the joint venture between Twist Bioscience and bitBiome.
In other recent news, Twist Bioscience Corporation has reported a robust 28% year-over-year growth in revenue for the fiscal third quarter of 2024, totaling $81.5 million.
This growth was primarily driven by the company's synthetic biology product line, including the Express Genes offering, and strong performance in Next-Generation Sequencing. The company's gross margin improved significantly to 43.3%, with an ambitious target to exceed 50% by the end of fiscal 2025.
Twist Bioscience also anticipates a 27% increase in total revenue for fiscal 2024 year-over-year, with projected Q4 revenue between $82 million and $83 million. The company's manufacturing facilities are poised to potentially yield over $700 million in annual revenue in the future.
In other developments, Twist Bioscience is expanding its market share in the NGS domain, launching an RNASeq portfolio, and seeing growth opportunities in the MRD market.
Despite potential geopolitical headwinds affecting its BioSecure product, the company remains confident in its competitive edge. These are some of the recent developments at Twist Bioscience.
InvestingPro Insights
Twist Bioscience Corporation (NASDAQ:TWST), a company at the forefront of DNA synthesis technology, has recently announced its collaboration with bitBiome Inc. to release a new Transaminase Enzyme Screening Kit. As the company continues to innovate and expand its product offerings, it's important for investors to consider the financial health and market performance of TWST. According to InvestingPro data, Twist Bioscience has a market capitalization of 2.52 billion USD, indicating a significant presence in the biotech sector.
InvestingPro Tips suggest that Twist Bioscience's stock has experienced considerable volatility, with a notable decline over the last week and analysts not expecting profitability for the current year. Nonetheless, the company has achieved a high return over the last year, emphasizing its potential for growth. Investors should note that while the company operates with a moderate level of debt, its liquid assets surpass its short-term obligations, which may offer some financial flexibility in its operations.
Despite not paying dividends, the company's revenue growth has been impressive, with a 25.37% increase over the last twelve months as of Q3 2024. This growth is reflective of Twist Bioscience's innovative approach to enzyme engineering and development in biocatalysis, as demonstrated by their latest product release in collaboration with bitBiome.
For those seeking additional insights, InvestingPro offers more tips on TWST, providing a comprehensive analysis to help investors make informed decisions. As of the latest update, there are six additional tips available on InvestingPro for Twist Bioscience, accessible at: https://www.investing.com/pro/TWST
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.